SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 77899.
  • 2
    Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 211323.
  • 3
    Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis 2006; 65: 2226.
  • 4
    Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795808.
  • 5
    Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005; 52: 201525.
  • 6
    Provvedini DM. The true results of the ECHODIAH study with diacerein [letter]. Osteoporos Int 2003; 14: 270.
  • 7
    Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, for the ECHODIAH nvestigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum 2001; 44: 253947.
  • 8
    Messent EA, Buckland-Wright JC, Blake GM. Fractal analysis of trabecular bone in knee osteoarthritis is a more sensitive marker of disease status than bone mineral density. Calcif Tissue Int 2005; 76: 41925.
  • 9
    Messent EA, Ward RJ, Tonkin CJ, Buckland-Wright C. Tibial cancellous bone changes in patients with knee osteoarthritis: a short-term longitudinal study using Fractal Signature Analysis. Osteoarthritis Cartilage 2005; 13: 46370.
  • 10
    Messent EA, Ward RJ, Tonkin CJ, Buckland-Wright C. Cancellous bone differences between knees with early, definite and advanced joint space loss: a comparative quantitative macroradiographic study. Osteoarthritis Cartilage 2005; 13: 3947.
  • 11
    Karvonen RL, Miller PR, Nelson DA, Granda JL, Fernandez-Madrid F. Periarticular osteoporosis in osteoarthritis of the knee. J Rheumatol 1998; 25: 218794.
  • 12
    Conaghan PG, Felson DT. Structural associations of osteoarthritis pain: lessons from magnetic resonance imaging [review]. Novartis Found Symp 2004; 260: 191201; discussion 201–5, 277–9.
  • 13
    Bergman AG, Willen HK, Lindstrand AL, Pettersson HT. Osteoarthritis of the knee: correlation of subchondral MR signal abnormalities with histopathologic and radiographic features. Skeletal Radiol 1994; 23: 4458.
  • 14
    Zanetti M, Bruder E, Romero J, Hodler J. Bone marrow edema pattern in osteoarthritic knees: correlation between MR imaging and histologic findings. Radiology 2000; 215: 83540.
  • 15
    Anderson-MacKenzie JM, Quasnichka HL, Starr RL, Lewis EJ, Billingham ME, Bailey AJ. Fundamental subchondral bone changes in spontaneous knee osteoarthritis. Int J Biochem Cell Biol 2005; 37: 22436.
  • 16
    Spector TD. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res 2003; 15: 4138.
  • 17
    Meyer J, Farmer R, Prenger MC. Risedronate but not alendronate slows disease progression in the guinea pig model of primary osteoarthritis [abstract]. J Bone Miner Res 2001; 16 Suppl 1: SA472.
  • 18
    Meyer JM, Dansereau SM, Farmer RW, Jeans GL, Prenger MC. Bisphosphonates structurally similar to risedronate (actonel) slow disease progression in the guinea pig model of primary osteoarthritis [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S307.
  • 19
    Hayami T, Pickarski M, Wesolowski GA, Mclane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004; 50: 1193206.
  • 20
    Muehleman C, Green J, Williams JM, Kuettner KE, Thonar EJ, Sumner DR. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002; 10: 22633.
  • 21
    Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, et al, for the Health, Aging and Body Composition Study. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004; 50: 351625.
  • 22
    Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001; 134: 5419.
  • 23
    Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002; 46: 317884.
  • 24
    Brown JP, Chines AA, Myers WR, Eusebio RA, Ritter-Hrncirik C, Hayes CW. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 2000; 26: 2637.
  • 25
    Burger H, van Daele PL, Odding E, Valkenburg HA, Hofman A, Grobbee DE, et al. Association of radiographically evident osteoarthritis with higher bone mineral density and increased bone loss with age: the Rotterdam Study. Arthritis Rheum 1996; 39: 816.
  • 26
    Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 1998; 22: 515.
  • 27
    Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ, for the Paget's Risedronate/Etidronate Study Group. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999; 106: 51320.
  • 28
    Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005; 7: R62533.
  • 29
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al, for the European Corticosteroid-Induced Osteoporosis Treatment Study. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15: 100613.
  • 30
    Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004; 20: 75764.
  • 31
    Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al, for the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 103949.
  • 32
    Buckland-Wright JC, Bird CF, Ritter-Hrncirik CA, Cline GA, Tonkin C, Hangartner TN, et al. X-ray technologists' reproducibility from automated measurements of the medial tibiofemoral joint space width in knee osteoarthritis for a multicenter, multinational clinical trial. J Rheumatol 2003; 30: 32938.
  • 33
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 34
    Buckland-Wright JC, Williams SA, Ward RJ. Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Ann Rheum Dis 1995; 54: 87280.
  • 35
    Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views. J Rheumatol 1999; 26: 266474.
  • 36
    Altman RD, Hochberg M, Murphy WA Jr, Wolfe F, Lequesne M. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage 1995; 3 Suppl A: 370.
  • 37
    Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29: 20915.
  • 38
    Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957; 16: 494501.
  • 39
    Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001; 45: 38491.
  • 40
    Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005; 64: 29–-33.
  • 41
    Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, for the VACT Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287: 6471.
  • 42
    Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004; 63: 9319.
  • 43
    Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F, Jordan JM, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44: 158798.
  • 44
    Mazzuca SA, Brandt KD, Katz BP, Lane KA, Bradley JD, Heck LW, et al. Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. Arthritis Rheum 2004; 51: 93340.
  • 45
    Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004; 31: 1506.
  • 46
    Lequesne M. Quantitative measurements of joint space during progression of osteoarthritis: “chondrometry.” In: KuettnerK, GoldbergV, editors. Osteoarthritic disorders. Rosemont (IL): American Academy of Orthopaedic Surgeons; 1995. p. 42744.
  • 47
    Ravaud P, Giraudeau B, Auleley GR, Edouard-Noel R, Dougados M, Chastang C. Assessing smallest detectable change over time in continuous structural outcome measures: application to radiological change in knee osteoarthritis. J Clin Epidemiol 1999; 52: 122530.
  • 48
    Buckland-Wright JC, Macfarlane DG, Jasani MK, Lynch JA. Quantitative microfocal radiographic assessment of osteoarthritis of the knee from weight bearing tunnel and semiflexed standing views. J Rheumatol 1994; 21: 173441.
  • 49
    Kirwan JR, Cushnaghan J, Dacre J, McAlindon T, Dieppe PA, Rogers J. Progression of joint space narrowing in knee osteoarthritis [abstract]. Arthritis Rheum 1992; 35 Suppl 9: S134.
  • 50
    Buckland-Wright JC, Macfarlane DG, Lynch JA, Jasani MK. Quantitative microfocal radiography detects changes in OA knee joint space width in patients in placebo controlled trial of NSAID therapy. J Rheumatol 1995; 22: 93743.
  • 51
    Sharma L, Song J, Felson DT, Cahue S, Shamiyeh E, Dunlop DD. The role of knee alignment in disease progression and functional decline in knee osteoarthritis. JAMA 2001; 286: 18895.
  • 52
    Dougados M, Gueguen A, Nguyen M, Berdah L, Lequesne M, Mazieres B, et al. Requirement for total hip arthroplasty: an outcome measure of hip osteoarthritis? J Rheumatol 1999; 26: 85561.
  • 53
    Adami S, Pavelka K, Cline GA, Hosterman MA, Barton IP, Cohen SB, et al. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 127885.
  • 54
    Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002; 46: 284756.
  • 55
    Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50: 24718.
  • 56
    Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 2002; 61: 5303.
  • 57
    Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone 2001; 28: 4614.
  • 58
    Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004; 34: 73646.
  • 59
    Garnero P, Peterfy C, Zaim S, Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005; 52: 28229.
  • 60
    Bingham CO III, Cline G, Adami S, Buckland-Wright C, Cohen S, Conaghan P, et al. Predictors of structural progression in knee osteoarthritis over 24 months [abstract]. Osteoarthritis Cartilage 2004; 12 Suppl B: S136.
  • 61
    Lohmander LS, Felson D. Can we identify a ‘high risk’ patient profile to determine who will experience rapid progression of osteoarthritis? Osteoarthritis Cartilage 2004; 12 Suppl A: S4952.
  • 62
    Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Labonte F, Beaudoin G, de Guise JA, et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum 2004; 50: 47687.